ANMCO position paper on the management of hypercholesterolaemia in patients with acute coronary syndrome.
Leonardo De LucaCarmine RiccioAlessandro NavazioSerafina ValenteManlio CiprianiMarco CordaAlfredo De NardoGiuseppina Maura FranceseCosimo NapoletanoEmanuele TizzaniLoris RonconPasquale CaldarolaMichele Massimo GuliziaDomenico GabrielliFabrizio OlivaFurio ColivicchiPublished in: European heart journal supplements : journal of the European Society of Cardiology (2023)
Patients suffering from acute coronary syndrome (ACS) present a high risk of recurrence and new adverse cardiovascular events after hospital discharge. Elevated plasma LDL-cholesterol (LDL-C) levels have been shown to be a causal factor for the development of coronary heart disease, and robust clinical evidence has documented that LDL-C levels decrease linearly correlates with a reduction in cardiovascular events. Recent studies have also demonstrated the safety and efficacy of an early and significant reduction in LDL-C levels in patients with ACS. In this position paper, Italian Association of Hospital Cardiologists proposes a decision algorithm on early adoption of lipid-lowering strategies at hospital discharge and short-term follow-up of patients with ACS, in the light of the multiple evidence generated in recent years on the treatment of hypercholesterolaemia and the available therapeutic options, considering current reimbursement criteria.
Keyphrases
- cardiovascular events
- acute coronary syndrome
- low density lipoprotein
- coronary artery disease
- cardiovascular disease
- percutaneous coronary intervention
- end stage renal disease
- antiplatelet therapy
- healthcare
- ejection fraction
- peritoneal dialysis
- newly diagnosed
- prognostic factors
- chronic kidney disease
- type diabetes
- adverse drug